4//SEC Filing
Henig Noreen 4
Accession 0001209191-23-043436
CIK 0001645666other
Filed
Jul 25, 8:00 PM ET
Accepted
Jul 26, 5:02 PM ET
Size
21.8 KB
Accession
0001209191-23-043436
Insider Transaction Report
Form 4
Henig Noreen
Chief Medical Officer
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−280,000→ 0 totalExercise: $5.45Exp: 2031-01-07→ Common Stock (280,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−180,000→ 0 totalExercise: $14.55Exp: 2032-01-04→ Common Stock (180,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−220,000→ 0 totalExercise: $6.84Exp: 2033-01-07→ Common Stock (220,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−300,000→ 0 totalExercise: $4.56Exp: 2030-04-30→ Common Stock (300,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+300,000→ 300,000 totalExercise: $2.28Exp: 2030-04-30→ Common Stock (300,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+280,000→ 280,000 totalExercise: $2.28Exp: 2031-01-07→ Common Stock (280,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+180,000→ 180,000 totalExercise: $2.28Exp: 2032-01-04→ Common Stock (180,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+220,000→ 220,000 totalExercise: $2.28Exp: 2033-01-07→ Common Stock (220,000 underlying)
Footnotes (5)
- [F1]Twenty-five percent (25%) of the shares subject to the option vested on May 1, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such vesting date.
- [F2]On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
- [F3]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
- [F4]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 5, 2022, subject to the Reporting Person continuing to provide service through each such date.
- [F5]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.
Documents
Issuer
Kezar Life Sciences, Inc.
CIK 0001645666
Entity typeother
Related Parties
1- filerCIK 0001810995
Filing Metadata
- Form type
- 4
- Filed
- Jul 25, 8:00 PM ET
- Accepted
- Jul 26, 5:02 PM ET
- Size
- 21.8 KB